Gilead Gets License To Compugen’s Potential First-In-Class IL-18 Target For Cancer

The company will pay $60m for rights to the preclinical asset COM503, which could be a new type of immuno-oncology drug.

tumor microenvironment — Gilead signed a deal with Compugen for an early novel immuno-oncology asset • Source: Shutterstock

Gilead Sciences, Inc. has partnered with Compugen Ltd. on the development and commercialization of a preclinical asset that could be a new kind of cancer immunotherapy. Gilead agreed to pay $60m up front for rights to Compugen’s COM503, which is a potential first-in-class antibody that blocks the interaction between IL-18 binding protein and IL-18, releasing natural IL-18 in the tumor microenvironment to inhibit cancer growth.

Key Takeaways

Gilead agreed to pay $60m up front for rights to Compugen’s COM503 for solid tumors.

The companies announced the collaboration on 19 December, under which Gilead will pay $60m up front and another $30m in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Deal Watch: Novartis Hopes To Ace Inflammatory Disease With Matchpoint Tie-Up

25 Jul 2025

• By Joseph Haas, Lisa Takagi, and Manas Mishra

Plus deals involving Lilly/Gate Bioscience, Concentra/iTeos, Nicox/Kowa, Ajax/Schrodinger, I-Mab/Bridge Health, Otsuka/Cantargia, JCR/Acumen and more.

Gateway To Africa: Natco Bids For 35.75% Of Adcock Ingram

24 Jul 2025

• By Anju Ghangurde

Natco to buy out Adcock Ingram’s minority shareholders in what’s possibly its biggest M&A investment, opening up substantial opportunities in South Africa and the region. If the offer goes through, it will result in the delisting of Adcock, with Bidvest and Natco co-owning the firm.

Scrip M&A Podcast: Is Biopharma M&A In A Holding Pattern Or A ‘New Normal’

23 Jul 2025

• By Joseph Haas

Scrip discusses the latest M&A activity and trends with CEO Shawn Titcomb of Allele Capital and Cheryl Reicin, a partner focused on international life sciences activity at Mintz.